One last min buy was about 1MM shares. IMO, when the real news starts to flow the dynamics will be overwhelming. Good S&S data will make the last couple of years woth it. All the best.
Best to all
A company like BD will only allow it's name to be used in PR's under certain conditions. Nice.
Lyon, Thanks ...your summary is helpful. Considering the expense and leverage an RP orphan approval could bring this is a clever PR. But, it is only one dot among many that we need to see connected . (see yawn)
"We are pleased to see continued progress in our orphan program for MANF in ophthalmological diseases," said Gerald E. Commissiong, President & CEO of Amarantus. "The results seen in this ocular tolerance study are encouraging for an initial clinical focus on MANF in orphan ocular diseases. This data will support the preparation of our orphan drug designation application with the FDA for MANF in one or more ocular disorders in the fourth quarter, including Retinitis Pigmentosa."
Worth the read, if you are AMBS long you will feel better....
" The company is seeking to enroll 72 patients (although we suspect the number may be closer to 100 once completed) and "bridge" the V1 and V2 data. What was presented at AAIC and C4CT was data from V1 only. We believe data from V2 is coming in September 2014. The data below show statistically significant separation on the CD69 biomarker from two new cell lines, CD19 and CD14, with an overall accuracy rate of around 80%.
Hi, I have been long for a couple of years and probably own far more of this stock than I could rationally justify. Expectations for strong news are very high, that may/may not be smart but there it is. Let's do this.
I was hoping that would happen and BOOOM....sweet
Important, it appears he has exprience actually making stuff as opposed to those who talk about making stuff.
" I WOULD FEEL BETTER WITH SOME SEPT DATES STUCK IN HERE BUT THIS IS A GOOD START..."As we enter the second half of 2014, we look forward to delivering a complete data set from our ongoing LP-002 clinical study for LymPro and preparing it for CLIA launch, completing the steps necessary to launch the Phase 2b clinical study for Eltoprazine, and delivering data from our MANF orphan ..."